Cancers & treatments·Regimen libraryCurative

Escalated BEACOPP

Checked 2026-09-09

Advanced-stage classical Hodgkin lymphoma in fit patients under 60, PET-adapted to 4-6 cycles

Also called BEACOPP, BEACOPPesc, eBEACOPP.

One cycle

every 21 days × 4-6 · about 12 weeks in total

21-day cycle × 4-6 (about 12 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days
Bleomycin Glycopeptide antibiotic (DNA-cleaving)	10 mg/m²	IV	D8
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative)	200 mg/m²	IV	D1-3
Doxorubicin Cytotoxic chemotherapy (anthracycline)	35 mg/m²	IV	D1
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	1,250 mg/m²	IV	D1
Vincristine Vinca alkaloid (microtubule inhibitor)	1.4 mg/m² (maximum 2 mg)	IV	D8
Procarbazine Alkylating-like methylhydrazine derivative	100 mg/m² once daily	Oral	D1-7
Prednisone Glucocorticoid	40 mg/m² once daily	Oral	D1-14

Cycles

4-6

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Built into the protocol

Notes

Higher cure rates than ABVD in advanced disease at the cost of more infertility and second cancers; HD18 showed 4 cycles suffice after a negative interim PET.
The BrECADD variant replaces bleomycin and vincristine with brentuximab vedotin and dacarbazine (HD21).

Used in

Hodgkin lymphoma

Products

BleomycinEtoposideDoxorubicinCyclophosphamideVincristineProcarbazinePrednisone

Source

Engert (GHSG HD15), Lancet 2012

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.